PE20191541A1 - Composiciones y metodos para inhibir la accion de la arginasa - Google Patents

Composiciones y metodos para inhibir la accion de la arginasa

Info

Publication number
PE20191541A1
PE20191541A1 PE2019001311A PE2019001311A PE20191541A1 PE 20191541 A1 PE20191541 A1 PE 20191541A1 PE 2019001311 A PE2019001311 A PE 2019001311A PE 2019001311 A PE2019001311 A PE 2019001311A PE 20191541 A1 PE20191541 A1 PE 20191541A1
Authority
PE
Peru
Prior art keywords
arginase
inhibit
compositions
alkyl
action
Prior art date
Application number
PE2019001311A
Other languages
English (en)
Inventor
Eric B Sjogren
Jim Li
Zandt Michael Van
Darren Whitehouse
Lijing Chen
Roland J Billedeau
Timothy F Stanton
Jr Gunnar E Jagdmann
Lene Raunkjaer Petersen
Francesco Parlati
Matthew I Gross
Original Assignee
Calithera Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60972528&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20191541(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Calithera Biosciences Inc filed Critical Calithera Biosciences Inc
Publication of PE20191541A1 publication Critical patent/PE20191541A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Referida a un compuesto derivado de formula (I'''), donde Rb es H, alquilo, alquenilo, alquinilo, entre otros; X es O o S; R1 y R2 son H, alquilo, alquenilo, entre otros; R3 es H, alquilo, alcoxi, SeH, entre otros; R4 es H o alquilo C1-C6. Tambien esta referida a una composicion farmaceutica. Dichos compuestos son inhibidores de arginasa y son utiles en el tratamiento del cancer
PE2019001311A 2016-12-22 2017-12-22 Composiciones y metodos para inhibir la accion de la arginasa PE20191541A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662438092P 2016-12-22 2016-12-22
US201662439614P 2016-12-28 2016-12-28
PCT/US2017/068307 WO2018119440A1 (en) 2016-12-22 2017-12-22 Compositions and methods for inhibiting arginase activity

Publications (1)

Publication Number Publication Date
PE20191541A1 true PE20191541A1 (es) 2019-10-23

Family

ID=60972528

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019001311A PE20191541A1 (es) 2016-12-22 2017-12-22 Composiciones y metodos para inhibir la accion de la arginasa

Country Status (32)

Country Link
US (4) US10287303B2 (es)
EP (2) EP3559009B1 (es)
JP (2) JP7018949B2 (es)
KR (1) KR102579849B1 (es)
CN (2) CN114989205A (es)
AU (2) AU2017382405B2 (es)
BR (1) BR112019012589B1 (es)
CA (1) CA3046987A1 (es)
CL (1) CL2019001711A1 (es)
CO (1) CO2019007839A2 (es)
CR (1) CR20190339A (es)
CY (1) CY1124483T1 (es)
DK (2) DK3559009T3 (es)
EC (1) ECSP19045511A (es)
ES (1) ES2881395T3 (es)
HR (1) HRP20210848T1 (es)
HU (1) HUE054272T2 (es)
IL (2) IL292677A (es)
LT (1) LT3559009T (es)
MD (1) MD3559009T2 (es)
MX (2) MX2019007471A (es)
MY (1) MY197478A (es)
NZ (1) NZ754364A (es)
PE (1) PE20191541A1 (es)
PH (1) PH12019501396A1 (es)
PL (1) PL3559009T3 (es)
PT (1) PT3559009T (es)
RS (1) RS61996B1 (es)
SG (2) SG10201911240PA (es)
SI (1) SI3559009T1 (es)
TW (1) TWI818902B (es)
WO (1) WO2018119440A1 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2632927T3 (pl) 2010-10-26 2016-09-30 Boroniany jako inhibitory arginazy
ES2928164T3 (es) 2015-10-19 2022-11-15 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
MX2018006207A (es) 2015-11-19 2018-09-05 Incyte Corp Compuestos heterociclicos como inmunomoduladores.
EA201891494A1 (ru) 2015-12-22 2019-01-31 Инсайт Корпорейшн Гетероциклические соединения в качестве иммуномодуляторов
EP3452476B1 (en) 2016-05-06 2021-12-15 Incyte Corporation Heterocyclic compounds as immunomodulators
ES2905980T3 (es) 2016-05-26 2022-04-12 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
HUE060256T2 (hu) 2016-06-20 2023-02-28 Incyte Corp Heterociklusos vegyületek mint immunmodulátorok
US20180016260A1 (en) 2016-07-14 2018-01-18 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018044783A1 (en) 2016-08-29 2018-03-08 Incyte Corporation Heterocyclic compounds as immunomodulators
TWI818902B (zh) * 2016-12-22 2023-10-21 美商卡利泰拉生物科技公司 用於抑制精胺酸酶活性的組合物及方法
EP3558973B1 (en) 2016-12-22 2021-09-15 Incyte Corporation Pyridine derivatives as immunomodulators
KR20190111025A (ko) 2016-12-22 2019-10-01 인사이트 코포레이션 면역조절제로서의 벤조옥사졸 유도체
WO2018119236A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
HRP20221216T1 (hr) * 2016-12-22 2022-12-23 Incyte Corporation Derivati tetrahidro imidazo[4,5-c]piridina kao induktori internalizacije pd-l1
CN108322295B (zh) 2017-01-17 2021-12-24 维沃移动通信有限公司 一种边带信息的发送方法、接收方法、发送端和接收端
PE20210176A1 (es) 2018-02-17 2021-01-29 Astrazeneca Ab Inhibidores de arginasa y sus metodos de uso
CA3094939A1 (en) 2018-03-29 2019-10-03 Oncoarendi Therapeutics S.A. Dipeptide piperidine derivatives
SG11202011165TA (en) 2018-05-11 2020-12-30 Incyte Corp Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-l1 immunomodulators
US11952392B2 (en) 2018-08-22 2024-04-09 Astrazeneca Ab Arginase inhibitors and methods of use thereof
US20220056051A1 (en) * 2018-12-18 2022-02-24 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use
FI3921033T3 (fi) * 2019-02-08 2023-09-15 Astrazeneca Ab Arginaasiestäjiä ja menetelmiä niiden käyttämiseksi
MX2022001671A (es) 2019-08-09 2022-05-13 Incyte Corp Sales de un inhibidor de pd-1/pd-l1.
CN110759843A (zh) * 2019-09-30 2020-02-07 东北师范大学 一种氟叠氮取代的四元杂环化合物的制备和应用
CN110734456A (zh) * 2019-11-06 2020-01-31 南京谷睿生物科技有限公司 一种化合物及其制备方法和医药上的应用
AU2020385113A1 (en) 2019-11-11 2022-05-19 Incyte Corporation Salts and crystalline forms of a PD-1/PD-L1 inhibitor
US11753413B2 (en) 2020-06-19 2023-09-12 Incyte Corporation Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
WO2021257857A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Naphthyridinone compounds as jak2 v617f inhibitors
WO2022006456A1 (en) 2020-07-02 2022-01-06 Incyte Corporation Tricyclic pyridone compounds as jak2 v617f inhibitors
KR20230057341A (ko) 2020-07-02 2023-04-28 인사이트 코포레이션 Jak2 v617f 억제제로서 삼환계 우레아 화합물
WO2022016195A1 (en) * 2020-07-17 2022-01-20 Incyte Corporation Processes for the preparation of arginase inhibitors and their synthetic intermediates
WO2022046989A1 (en) 2020-08-27 2022-03-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
JP2023548859A (ja) 2020-11-06 2023-11-21 インサイト・コーポレイション Ｐｄ－１／ｐｄ－ｌ１阻害剤ならびにその塩及び結晶形態を作製するためのプロセス
US11760756B2 (en) 2020-11-06 2023-09-19 Incyte Corporation Crystalline form of a PD-1/PD-L1 inhibitor
WO2022099018A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Process of preparing a pd-1/pd-l1 inhibitor
CN112387262B (zh) * 2020-11-10 2021-12-07 泰州学院 一种基于光催化交联蛋白的手性固定相的制备方法、手性固定相及应用
WO2022140231A1 (en) 2020-12-21 2022-06-30 Incyte Corporation Deazaguaine compounds as jak2 v617f inhibitors
TW202228720A (zh) 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法
AR125273A1 (es) 2021-02-25 2023-07-05 Incyte Corp Lactamas espirocíclicas como inhibidores de jak2 v617f
WO2023133505A2 (en) * 2022-01-07 2023-07-13 The Trustees Of Columbia University In The City Of New York Inhibition of kynurenine synthesis and/or signaling to treat leukemia and myelodysplasia
US20230295124A1 (en) 2022-03-17 2023-09-21 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
WO2024086273A1 (en) 2022-10-21 2024-04-25 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
JP3979783B2 (ja) 1997-07-29 2007-09-19 アルコン ラボラトリーズ インコーポレイテッド ガラクトマンナンポリマー及びホウ酸塩を含む眼科組成物
AU9797998A (en) 1997-10-10 1999-05-03 Trustees Of The University Of Pennsylvania, The Compositions and methods for inhibiting arginase activity
AU2483599A (en) 1998-01-29 1999-08-16 Sepracor, Inc. Pharmaceutical uses of optically pure (-)-bupropion
US20040063666A1 (en) 1998-10-09 2004-04-01 David Christianson Compositions for inhibiting arginase activity
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
US6720188B2 (en) 2000-07-06 2004-04-13 Fal Diagnostics Methods and kits for the detection of arginine compounds
CA2431080A1 (en) 2003-06-02 2004-12-02 Catherine Adele O'brien Enhancement of anticancer immunity through inhibition of arginase
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
EP1654002B2 (en) 2003-08-07 2014-01-29 Allergan, Inc. Compositions for delivery of therapeutics into the eyes
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
EP1915143A4 (en) 2005-07-01 2009-11-11 Univ Johns Hopkins ARGINASE II: TARGET TREATMENT FOR THE AGING HEART AND HEART FAILURE
WO2007095050A2 (en) 2006-02-09 2007-08-23 Incyte Corporation N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase
WO2008036652A2 (en) 2006-09-19 2008-03-27 Incyte Corporation Amidines as modulators of indoleamine 2,3-dioxygenase
JP5319532B2 (ja) 2006-09-19 2013-10-16 インサイト・コーポレイション インドールアミン２，３−ジオキシゲナーゼのモジュレーターとしてのｎ−ヒドロキシアミジノヘテロサイクル
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
WO2008036643A2 (en) 2006-09-19 2008-03-27 Incyte Corporation Amidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
US20080182882A1 (en) 2006-11-08 2008-07-31 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
KR101532256B1 (ko) 2006-11-22 2015-06-29 인사이트 코포레이션 키나제 억제제로서의 이미다조트리아진 및 이미다조피리미딘
JP5583592B2 (ja) 2007-11-30 2014-09-03 ニューリンク ジェネティクス コーポレイション Ｉｄｏ阻害剤
WO2009132238A2 (en) 2008-04-24 2009-10-29 Newlink Genetics Ido inhibitors
HUE036813T2 (hu) 2008-07-08 2018-07-30 Incyte Holdings Corp 1,2,5-Oxadiazolok mint indolamin-2,3-dioxigenáz inhibitorok
DK2389352T3 (da) 2009-01-26 2019-07-29 Univ Pennsylvania Arginaseinhibitorer og anvendelsesfremgangsmåder
WO2011082245A2 (en) 2009-12-31 2011-07-07 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
EP2547366A4 (en) 2010-03-18 2013-08-07 Univ Colorado State Res Found INHIBITING AGENTS OF SUPPRESSIVE MYELOID CELLS
WO2011133653A1 (en) 2010-04-22 2011-10-27 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
DK2563771T3 (en) 2010-04-24 2016-02-29 Viamet Pharmaceuticals Inc Metalloenzyminhibitorforbindelser
PT2603514T (pt) * 2010-08-10 2018-11-09 Rempex Pharmaceuticals Inc Derivados cíclicos de éster de ácido borónico e suas utilizações terapêuticas
EP2609098B1 (en) 2010-08-27 2016-07-13 Merck Patent GmbH Triazolopyrazine derivatives
PL2632927T3 (pl) * 2010-10-26 2016-09-30 Boroniany jako inhibitory arginazy
AU2011320565A1 (en) 2010-10-28 2013-05-23 Innocrin Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
JP5828343B2 (ja) 2010-11-13 2015-12-02 イノクリン ファーマシューティカルズ，インコーポレイテッド 金属酵素阻害化合物
CA2820718A1 (en) 2010-12-13 2012-06-21 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
CA2824599C (en) 2010-12-31 2020-03-10 Corridor Pharmaceuticals, Inc. Arginase inhibitors and methods of use thereof
NO2694640T3 (es) 2011-04-15 2018-03-17
CN103764646A (zh) 2011-06-19 2014-04-30 威尔金制药有限公司 金属酶抑制剂化合物
EA025406B1 (ru) 2011-06-19 2016-12-30 Ваймет Фармасьютикалс, Инк. Соединения, ингибирующие металлоферменты
IN2014DN00286A (es) 2011-06-23 2015-06-05 Viamet Pharmaceuticals Inc
JP2014525442A (ja) 2011-08-30 2014-09-29 ヴィアメット ファーマスーティカルズ，インコーポレイテッド 金属酵素阻害化合物
WO2013059437A1 (en) 2011-10-19 2013-04-25 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
AU2012325909B2 (en) * 2011-10-20 2016-06-09 Glaxosmithkline Llc Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators
EA025437B1 (ru) 2011-12-11 2016-12-30 Ваймет Фармасьютикалс, Инк. Соединения, ингибирующие металлоферменты
AU2013209516A1 (en) 2012-01-20 2014-08-28 Viamet Pharmaceuticals (NC), Inc. Metalloenzyme inhibitor compounds
SG11201404234YA (en) 2012-01-28 2014-08-28 Merck Patent Gmbh Triazolo[4,5-d]pyrimidine derivatives
CA2865040C (en) 2012-02-21 2020-07-14 Merck Patent Gmbh Cyclic diaminopyrimidine derivatives
JP6479476B2 (ja) 2012-02-21 2019-03-06 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ ＳｙｋチロシンキナーゼインヒビターおよびＧＣＮ２セリンキナーゼインヒビターとしての８−置換２−アミノー［１，２，４］トリアゾロ［１，５−Ａ］ピラジン類
WO2013131609A1 (en) 2012-03-07 2013-09-12 Merck Patent Gmbh Triazolopyrazine derivatives
EP2852598B3 (en) 2012-04-18 2016-10-19 Mars, Incorporated Ring constrained analogs as arginase inhibitors
ES2618004T3 (es) 2012-08-07 2017-06-20 Merck Patent Gmbh Derivados de piridopirimidina como inhibidores de proteínas quinasas
EP2894981B1 (en) 2012-09-12 2019-12-04 Dow AgroSciences LLC Metalloenzyme inhibitor compounds
JP2016508487A (ja) 2013-01-28 2016-03-22 ヴィアメット ファーマスーティカルズ，インコーポレイテッド 金属酵素阻害剤化合物
CN105026398B (zh) 2013-03-05 2018-05-18 默克专利股份公司 用于治疗疾病诸如癌症的***并[4,5-d]嘧啶衍生物
EP2964648B1 (en) 2013-03-05 2016-11-16 Merck Patent GmbH 9-(aryl or heteroaryl)-2-(pyrazolyl, pyrrolidinyl or cyclopentyl)aminopurine derivatives as anticancer agents
MX361375B (es) 2013-03-14 2018-12-05 Newlink Genetics Corp Compuestos triciclicos como inhibidores de la inmunosupresion mediada por el metabolismo del triptofano.
WO2014141110A2 (en) 2013-03-14 2014-09-18 Curadev Pharma Pvt. Ltd. Aminonitriles as kynurenine pathway inhibitors
WO2014186035A1 (en) 2013-03-14 2014-11-20 Curadev Pharma Private Ltd. Inhibitors of the kynurenine pathway
ES2733546T3 (es) 2013-03-15 2019-11-29 Bristol Myers Squibb Co Inhibidores de IDO
DK2970155T3 (en) 2013-03-15 2018-08-06 Bristol Myers Squibb Co INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE (IDO)
CN105164136B (zh) 2013-05-06 2017-12-22 默克专利股份公司 作为激酶抑制剂的大环化合物
JP6387401B2 (ja) 2013-05-28 2018-09-05 ヴィアメット ファーマスーティカルズ（エヌシー），インコーポレイテッド 殺真菌組成物
CN105473550B (zh) 2013-07-01 2019-02-15 百时美施贵宝公司 Ido抑制剂
EA201690152A1 (ru) 2013-07-11 2016-05-31 Бристол-Майерс Сквибб Компани Ингибиторы ido
WO2015017402A1 (en) 2013-07-29 2015-02-05 Board Of Regents Of The University Of Nebraska Compositions and methods for the treatment of biofilm infections
EA029981B1 (ru) 2013-08-27 2018-06-29 Бристол-Майерс Сквибб Компани Ингибиторы ido
MX2016005283A (es) 2013-10-25 2017-02-20 Pharmacyclics Llc Tratamiento que utiliza inhibidores de tirosina quinasa de bruton e inmunoterapia.
KR102617531B1 (ko) 2013-11-08 2023-12-27 인사이트 홀딩스 코포레이션 인돌아민 2,3-디옥시게나제 억제제의 합성 방법
KR20160108568A (ko) 2014-02-04 2016-09-19 인사이트 코포레이션 암을 치료하기 위한 pd-1 길항제 및 ido1 억제제의 조합
KR20160144410A (ko) 2014-04-15 2016-12-16 다우 아그로사이언시즈 엘엘씨 살진균제로서의 금속효소 억제제 화합물
KR20160145640A (ko) 2014-04-15 2016-12-20 다우 아그로사이언시즈 엘엘씨 살진균제로서의 금속효소 억제제 화합물
CA2951259A1 (en) 2014-06-06 2015-12-10 Flexus Biosciences, Inc. Immunoregulatory agents
TW201619133A (zh) 2014-08-21 2016-06-01 裘拉德製藥私人有限公司 新穎亞氨腈（ｉｍｉｎｏｎｉｔｒｉｌｅ）衍生物
US9771370B2 (en) 2014-09-05 2017-09-26 Merck Patent Gmbh Compounds for the inhibition of indoleamine-2,3-dioxygenase
CN105879030A (zh) 2014-09-30 2016-08-24 复旦大学 ***的增效药物复合物及其制备方法
GB201417369D0 (en) 2014-10-01 2014-11-12 Redx Pharma Ltd Compounds
WO2016057986A1 (en) 2014-10-10 2016-04-14 The Trustees Of Columbia University In The City Of New York Tandem epitope constructs for presentation of cd4 and cd8 epitopes and uses thereof
GB201418300D0 (en) 2014-10-15 2014-11-26 Redx Pharma Ltd Compounds
UY36391A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen
UY36390A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
EP3215141A4 (en) 2014-11-05 2018-06-06 Flexus Biosciences, Inc. Immunoregulatory agents
WO2016130501A1 (en) 2015-02-09 2016-08-18 Incyte Corporation Aza-heteroaryl compounds as pi3k-gamma inhibitors
CN107405404A (zh) 2015-03-20 2017-11-28 塞米·欧尤·奥皮约 苏拉明和精氨酸酶抑制剂在恶性肿瘤中的用途
KR20170134981A (ko) 2015-04-03 2017-12-07 브리스톨-마이어스 스큅 컴퍼니 암의 치료를 위한 인돌아민-2,3-디옥시게나제의 억제제
AU2016243939B2 (en) 2015-04-03 2020-09-03 Incyte Holdings Corporation Heterocyclic compounds as LSD1 inhibitors
TW201705955A (zh) 2015-05-14 2017-02-16 輝瑞大藥廠 包含吡咯啶－２，５－二酮ｉｄｏ１抑制劑及抗－ｐｄ１／抗－ｐｄ－ｌ１抗體之組合療法
WO2016196890A1 (en) 2015-06-04 2016-12-08 Vtv Therapeutics Llc Inhibitors of hexokinase and methods of use thereof
AU2016281620B2 (en) 2015-06-23 2021-07-22 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
EP4011887A1 (en) * 2015-10-30 2022-06-15 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
TWI818902B (zh) * 2016-12-22 2023-10-21 美商卡利泰拉生物科技公司 用於抑制精胺酸酶活性的組合物及方法

Also Published As

Publication number Publication date
CN110382508A (zh) 2019-10-25
AU2017382405A1 (en) 2019-06-27
EP3559009A1 (en) 2019-10-30
PH12019501396A1 (en) 2019-12-02
US20180222926A1 (en) 2018-08-09
CA3046987A1 (en) 2018-06-28
BR112019012589A2 (pt) 2019-11-19
JP2022066199A (ja) 2022-04-28
NZ754364A (en) 2023-04-28
CR20190339A (es) 2020-01-10
MD3559009T2 (ro) 2021-07-31
US20200339607A1 (en) 2020-10-29
MX2020013649A (es) 2021-02-26
SI3559009T1 (sl) 2021-08-31
SG10201911243WA (en) 2020-02-27
JP7018949B2 (ja) 2022-02-14
PL3559009T3 (pl) 2021-10-25
IL267532B (en) 2022-06-01
US20190330244A1 (en) 2019-10-31
HUE054272T2 (hu) 2021-09-28
TW201828948A (zh) 2018-08-16
KR20190119579A (ko) 2019-10-22
ES2881395T3 (es) 2021-11-29
KR102579849B1 (ko) 2023-09-18
US11021495B2 (en) 2021-06-01
IL292677A (en) 2022-07-01
TWI818902B (zh) 2023-10-21
CN110382508B (zh) 2022-08-02
ECSP19045511A (es) 2019-10-31
RS61996B1 (sr) 2021-07-30
MX2019007471A (es) 2019-11-05
EP3559009B1 (en) 2021-04-07
DK3842442T3 (da) 2024-02-05
US10287303B2 (en) 2019-05-14
WO2018119440A1 (en) 2018-06-28
CL2019001711A1 (es) 2020-01-17
LT3559009T (lt) 2021-06-25
CO2019007839A2 (es) 2019-10-21
MY197478A (en) 2023-06-19
EP3842442B1 (en) 2023-11-01
BR112019012589B1 (pt) 2022-11-29
AU2022201072A1 (en) 2022-03-10
SG10201911240PA (en) 2020-02-27
DK3559009T3 (da) 2021-05-03
US10597411B2 (en) 2020-03-24
JP2020514271A (ja) 2020-05-21
CY1124483T1 (el) 2022-07-22
EP3842442A1 (en) 2021-06-30
HRP20210848T1 (hr) 2021-07-09
CN114989205A (zh) 2022-09-02
PT3559009T (pt) 2021-05-04
US20210261573A1 (en) 2021-08-26
AU2017382405B2 (en) 2021-12-16
IL267532A (en) 2019-08-29

Similar Documents

Publication Publication Date Title
PE20191541A1 (es) Composiciones y metodos para inhibir la accion de la arginasa
PH12019550050A1 (en) Isoxazole analogs as fxr agonists and methods of use thereof
PE20211782A1 (es) Compuestos de 5-cloro-2-difluorometoxifenil pirazolopirimidina, composiciones y metodos de uso de los mismos
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
EA201991399A1 (ru) Аминотриазолопиридиновые соединения и их применение в лечении рака
EA201990495A1 (ru) Биарильные соединения, применимые в качестве иммуномодуляторов
BR112017003658A2 (pt) composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica.
EA201891203A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
PE20170247A1 (es) Derivados de pirrolidina-2,5-diona, composiciones farmaceuticas y metodos para usar como inhibidores ido1
PE20180024A1 (es) Triazolopirazinonas como inhibidores de pde1
MX2016016516A (es) Inhibidores de fosfatidilinositol 3-cinasa.
PE20171241A1 (es) Terapias de combinacion para el tratamiento de canceres
PE20142098A1 (es) Compuestos terapeuticamente activos y sus metodos de uso
MX2016016530A (es) Inhibidores de fosfatidilinositol 3-quinasa.
PE20150400A1 (es) Benzamidas n-sustituidas y su uso en el tratamiento del dolor
MX2016016528A (es) Inhibidores de fosfatidilinositol 3-quinasa.
CO2019003482A2 (es) Compuestos derivados de ciclobutano o azetidina 1,3 disustituidos como inhibidores de la prostaglandina d sintasa hematopoyética
PE20161236A1 (es) Compuesto de triazina y su uso para fines medicos
CO2019004978A2 (es) Compuestos terapéuticos y métodos para utilizarlos
AR078278A1 (es) Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro.
UY37764A (es) Nuevos compuestos inhibidores de la prostaglandina d sintasa hematopoyética (h-pgds)
PE20170148A1 (es) Compuestos de 1,3, 4-tiadiazol y uso de los mismos para el tratamiento del cancer
PE20171335A1 (es) Inhibidores de gingipaina de lisina
MX2018013164A (es) Compuestos novedosos de imidazopiridina sustituida como inhibidores de indolamina-2,3-dioxigenasa y/o triptofano-2,3-dioxigenasa.
PE20191103A1 (es) Inhibidores de dopamina-b-hidroxilasa